Arterial hypertension (AH) remains to this day one of the main problems in cardiology. It is one of the leading risk factors for cardiovascular complications and death, is diagnosed in one third of the world’s population and leads to the death of almost 10 million people every year. It is the poor control of blood pressure in patients with hypertension that is accompanied by a significant increase in the risk of cardiovascular accidents. It should be noted that the high efficacy of Angiotensin II receptor blockers demonstrated in numerous studies, strengthens their position as components of the first line of therapy in many cardiovascular diseases. With the advent of new antihypertensive drugs that are highly effective in influencing the daily blood pressure profile, as well as good organ protection, new opportunities for good blood pressure control and protection of target organs are opening up. In particular, azilsartan, a new representative of the angiotensin II receptor blockers class, effectively and safely reduces blood pressure, has a beneficial effect on the glycemic profile and glomerular filtration rate in patients with hypertension, diabetes mellitus and chronic kidney disease. Its high antihypertensive activity and favorable safety profile ensure better patient adherence to long-term therapy and optimal blood pressure control.